KCNQ2 and epilepsy: Our findings greatly expand knowledge regarding the molecular basis of KCNQ2-related epilepsy including functional comparisons among variants associated with the spectrum of clinical severity and offer new information about the heterogeneity of retigabine responsiveness that will contribute to its emerging use for precision therapy of this monogenic epilepsy.